Site search

Clear filter
2811 results for '' found
ARTEMIS- Effects of Ziltivekimab versus placebo on cardiovascular outcomes in patients with acute myocardial infarction (105277)
ARTEMIS- Effects of Ziltivekimab versus placebo on cardiovascular outcomes in patients with acute myocardial infarction (105277)
/
A Phase 1/2a Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-DUX4 in Adult Patients with Facioscapulohumeral Muscular Dystrophy Type 1 (N
A Phase 1/2a Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-DUX4 in Adult Patients with Facioscapulohumeral Muscular Dystrophy Type 1 (N
/
A Phase 1/2a Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-DM1 in Subjects With Type 1 Myotonic Dystrophy Who Are =18 to = 65 Years (NC
A Phase 1/2a Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-DM1 in Subjects With Type 1 Myotonic Dystrophy Who Are =18 to = 65 Years (NC
/
A Phase 1 Placebo-Controlled Dose Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-ATXN2 in Adult Subjects With Spinocerebellar Ataxia Type 2 (
A Phase 1 Placebo-Controlled Dose Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-ATXN2 in Adult Subjects With Spinocerebellar Ataxia Type 2 (
/
Australasian Resuscitation In Sepsis Evaluation: FLUid or vasopressors In emergency Department Sepsis (NCT04569942)
Australasian Resuscitation In Sepsis Evaluation: FLUid or vasopressors In emergency Department Sepsis (NCT04569942)
/
A Randomized, Double-Blinded, Placebo-Controlled, Phase 3, Parallel-Group Design Study Evaluating the Efficacy and Safety of Efgartigimod PH20 SC Administered by Prefilled Syringe in Adult Partic
A Randomized, Double-Blinded, Placebo-Controlled, Phase 3, Parallel-Group Design Study Evaluating the Efficacy and Safety of Efgartigimod PH20 SC Administered by Prefilled Syringe in Adult Partic
/
A Phase 3, randomized, double-blind, placebo-controlled, parallel-group, 3-arm, multinational, multicenter study to evaluate the efficacy and safety of amlitelimab by subcutaneous injection in pa
A Phase 3, randomized, double-blind, placebo-controlled, parallel-group, 3-arm, multinational, multicenter study to evaluate the efficacy and safety of amlitelimab by subcutaneous injection in pa
/
A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled, 60-Week, Phase II Clinical Trial of Ambroxol and Doxycycline in Moderate Severity Parkinson’s Disease (ACTRN12623000843651)
A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled, 60-Week, Phase II Clinical Trial of Ambroxol and Doxycycline in Moderate Severity Parkinson’s Disease (ACTRN12623000843651)
/
A Randomised, Double-Blind, Parallel-Group,Placebo-Controlled, 60-Week, Phase II Clinical Trial of Three Re-Purposed Medications in Moderate Severity Parkinson’s Disease (ACTRN12620000560998)
A Randomised, Double-Blind, Parallel-Group,Placebo-Controlled, 60-Week, Phase II Clinical Trial of Three Re-Purposed Medications in Moderate Severity Parkinson’s Disease (ACTRN12620000560998)
/
APG2575AU101 A Phase Ib/II Study of APG-2575 in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML), Mixed Phenotype Acute Leukemia (MPAL), Chronic Myelomonocytic Leukemia
APG2575AU101 A Phase Ib/II Study of APG-2575 in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML), Mixed Phenotype Acute Leukemia (MPAL), Chronic Myelomonocytic Leukemia
/